IDEAYA Biosciences, Inc. (IDYA)

NASDAQ: IDYA · IEX Real-Time Price · USD
17.98
+0.21 (1.18%)
Dec 2, 2022 4:00 PM EST - Market closed
1.18%
Market Cap 854.98M
Revenue (ttm) 49.87M
Net Income (ttm) -52.67M
Shares Out 40.30M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE 4.65
Dividend n/a
Ex-Dividend Date n/a
Volume 421,859
Open 17.67
Previous Close 17.77
Day's Range 17.25 - 18.2
52-Week Range 8.14 - 24.09
Beta 0.98
Analysts Buy
Price Target 24.61 (+36.9%)
Earnings Date Nov 21, 2022

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers ha... [Read more]

Industry Biotechnology
IPO Date May 23, 2019
CEO Yujiro Hata
Employees 95
Stock Exchange NASDAQ
Ticker Symbol IDYA
Full Company Profile

Financial Performance

In 2021, IDYA's revenue was $27.94 million, an increase of 43.01% compared to the previous year's $19.54 million. Losses were -$49.76 million, 44.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is 24.61, which is an increase of 36.87% from the latest price.

Price Target
$24.61
(36.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, ...

SOUTH SAN FRANCISCO, Calif. , Nov. 29, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

4 days ago - PRNewsWire

IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D.

Former Senior Vice President and Head of Early Oncology Development and Clinical Research at Pfizer will lead IDEAYA's clinical development efforts as Chief Medical Officer Over twenty-five years of exp...

5 days ago - PRNewsWire

Wall Street Analysts Think IDEAYA Biosciences, Inc. (IDYA) Could Surge 32%: Read This Before Placing a Bet

The mean of analysts' price targets for IDEAYA Biosciences, Inc. (IDYA) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

2 weeks ago - Zacks Investment Research

IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 106.15% and 271.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

3 weeks ago - Zacks Investment Research

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 Reported Phase 2 interim clinical dat...

3 weeks ago - PRNewsWire

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

1 month ago - PRNewsWire

IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-...

First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors. First patient dosed in IDE397 combination with taxane in...

1 month ago - PRNewsWire

IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Add...

SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 8,761,905 shares of its common stoc...

2 months ago - PRNewsWire

IDEAYA Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 7,619,048 shares of its common stoc...

2 months ago - PRNewsWire

IDEAYA Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80.0 million of shares of its common stock in...

2 months ago - PRNewsWire

Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study

Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.

2 months ago - Zacks Investment Research

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination...

Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patients Tumor shrinkage observed in 31 of 35 (89%) ...

2 months ago - PRNewsWire

IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uv...

- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear Hospital, Melbourne - Preliminary signals of clini...

2 months ago - PRNewsWire

IDEAYA Biosciences to Participate in Investor Conferences in September 2022

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and deve...

3 months ago - PRNewsWire

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Th...

Preclinical development milestone achieved in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC as combo with niraparib Potential to realize preclinic...

3 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0% and 26.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022 is anticipated to fund planned operations into 2025 Initiated IDE397 Phase 2 monotherapy expans...

3 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in M...

Entered into Clinical Trial Collaboration and Supply Agreement with Amgen to clinically evaluate IDE397, IDEAYA's investigational MAT2A inhibitor, in combination with AMG 193, Amgen's investigational MT...

4 months ago - PRNewsWire

IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Colla...

Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with nirapa...

5 months ago - PRNewsWire

IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , June 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

5 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 2025 Targeting initiation of IDE397 Phase 1/2 m...

6 months ago - PRNewsWire

IDEAYA Biosciences to Participate in Investor Conferences in May 2022

SAN FRANCISCO , May 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targe...

7 months ago - PRNewsWire

IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Mel...

-  Darovasertib designated as an Orphan Drug by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, and potential statutory marketing exclusivity -  Targeting a clinical dat...

7 months ago - PRNewsWire